Fig. 2: CARF enrichment correlates with metastatic progression in clinical tumors. | Oncogenesis

Fig. 2: CARF enrichment correlates with metastatic progression in clinical tumors.

From: CARF enrichment promotes epithelial–mesenchymal transition via Wnt/β-catenin signaling: its clinical relevance and potential as a therapeutic target

Fig. 2

a Immunohistochemical staining showing CARF expression in normal, infiltrating, and metastatic breast cancer patient tumors; their quantitative levels shown on right. b, CARF levels in patients with normal to infiltrating (sub-group #1) and infiltrating to metastatic (sub-group #2) breast tumors in different age groups; quantitation shown below. c Expression of CARF in normal and metastatic tumor sections of intestine, liver and skin; quantitation shown on right. d Quantitation of CARF expression in normal and malignant breast, prostate, skin, liver, and kidney tumors sections; and in normal, lobular, and ductal breast cancer immunohistological sections retrieved from Human Protein Atlas (e)

Back to article page